TABLE 1.
Model inputs.
| Cost in different states | Base case | Range tested | Distribution | Source |
|---|---|---|---|---|
| Recurrent VTE | 3,853 | 2,697–5,009 | Gamma | LI |
| MB | 3,834 | 2,684–4,984 | Gamma | Wu(Wu et al.) |
| CRNMB | 8.25 | 5.77–10.72 | Gamma | Wu(Wu et al.) |
| Warfarin monitoring (per time) | 10.98 | 7.69–14.27 | Gamma | EMR |
| Utilities | ||||
| VTE on-treatment | 0.94 | 0.75–1.00 | Beta | Mccullagh (Mccullagh et al., 2012) |
| Recurrent VTE | 0.76 | 0.57–0.95 | Beta | Uniform |
| MB | 0.55 | 0.15–0.86 | Beta | Hogg (Hogg et al., 2013) |
| CRNMB | 0.61 | 0.68–0.51 | Beta | Locadia (Locadia et al., 2004) |
| Death | 0.00 | - | Beta | Definition |
| VTE off-treatment | 0.75 | 0.45–0.91 | Beta | - |
| API | −0.0020 | 0.000–0.0060 | Beta | Gage(Gage et al., 1996) |
| VKA | −0.0130 | 0.000–0.0047 | Beta | Gage(Gage et al., 1996) |
| RIV | −0.002 | 0.000–0.006 | Beta | Gage(Gage et al., 1996) |
| DAB | −0.002 | 0.000–0.005 | Beta | Gage(Gage et al., 1996) |
| Cost of drugs | ||||
| API | 5,877.399 | 639.764–14,326.537 | Gamma | EMR |
| RIV | 3,072.136 | 465.279–18,391.693 | Gamma | EMR |
| DAB | 3,926.160 | 970.546–13,152.974 | Gamma | EMR |
| VKA | 4,325.386 | 612.487–10,287.356 | Gamma | EMR |
VTE, venous thromboembolism; MB, major bleeding; CRNMB, clinically relevant non-major bleeding; API, apixaban; VKA, vitamin K antagonist; RIV, rivaroxaban; DAB, dabigatran; EMR, electronic medical records.